Search Results
Jun 04, 2026, 10:30 ET Made Scientific and Pluristyx Launch Integrated iPSC Development & Manufacturing Partnership to Advance Next-Generation iPSC-derived Cell Therapies
Scientific's iPSC and iPSC-derivative supply and development partner, providing client access to RUO and GMP-ready iPSC lines and derivative cell types for use across R&D, clinical, and commercial manufacturing under FDA, EMA Annex I, and global regulatory compliance."The demand for iPSC-derived
More news about: Made Scientific, Inc.
Jun 02, 2026, 09:02 ET A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company
capital is across the small end of this field.Century Therapeutics, Inc. (NASDAQ: IPSC) represents the better-capitalized end of the cell-therapy spectrum. The company develops allogeneic, iPSC-derived NK and engineered immune-cell therapies — including a CAR-iNK candidate — using a proprietary
More news about: USA News Group
May 28, 2026, 09:15 ET Anti-Aging Cell Therapy Reaches Major GMP Milestone as Wave of Clinical Advancements Gain Momentum
highlighting a strategic collaboration with Mayo Clinic to advance development of SC451, a hypoimmune (HIP)-modified, induced pluripotent stem cell (iPSC)-derived pancreatic islet cell therapy for type 1 diabetes. In connection with the collaboration, Mayo Clinic made an approximately $25.0 million equity
More news about: USA News Group
May 20, 2026, 09:50 ET Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets
(NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived off-the-shelf cellular immunotherapies to patients for broad accessibility, recently
More news about: Market News Updates
May 19, 2026, 09:00 ET Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes
publicly listed NK cell therapy companies, with a platform built around induced pluripotent stem cell (iPSC)-derived NK cell therapies for the treatment of cancer and autoimmune disease. Fate's iPSC platform offers an off-the-shelf manufacturing approach that contrasts mechanistically with engager molecule
More news about: Equity Insider
May 18, 2026, 20:00 ET Innovent Showcased Clinical and Preclinical Results of Next-Generation Autoimmune and Ophthalmology Pipeline at the 2026 ATS and ARVO Conferences
proliferation of human lung and dermal fibroblasts. Besides, IBI3038 significantly inhibited collapse of alveoli (atelectasis) and collagen deposits on human iPSC induced lung organoids, better than IL-6 mAb. Lastly, in a mouse model, dual blockade of IL-6 and IGF-1R significantly suppressed lung fibrosis development
More news about: Innovent Biologics
May 14, 2026, 09:00 ET Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth Phase
(NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies broadly to patients with cancer and autoimmune diseases, is
More news about: Market News Updates
May 14, 2026, 08:00 ET Jetstream Venture Fund Invests in Wonderlab Bio, Expanding its High-Growth HealthTech Portfolio
focuses on knee osteoarthritis, a condition affecting 32.5 million Americans and currently lacking any FDA-approved cell therapy. Their injectable, iPSC-derived chondrocyte therapy targets cartilage regeneration without surgery, at a projected price point below the cost of a traditional joint replacement.The
More news about: Jetstream Venture Fund
May 12, 2026, 11:00 ET Porton Advanced and Dark Horse Consulting Group Announce Memorandum of Understanding Providing A Streamlined Path to Conducting IITs in China
end-to-end GMP manufacturing infrastructure, spanning lentiviral vectors, AAV, mRNA/LNP, plasmids, and engineered cell therapies including CAR-T, CAR-NK, and iPSC-derived products. Together, the two organizations will offer client companies a cost-effective and rapid pathway into clinical-stage manufacturing,
More news about: Porton Advanced
May 12, 2026, 09:00 ET Porton Advanced Stem Cell Exosomes Granted INCI Status, Advancing into Global Cosmetic Ingredient Market
exosome manufacturing platformFlexible Cell Culture Systems: Supports multiple cell lines including HEK293, MSC, K562, and iPSC.Scalable and Robust Processes: Scalable from 2L to 50L bioreactors, enabling seamless transition from R&D to commercial production.High
More news about: Porton Advanced
May 12, 2026, 04:13 ET Porton Advanced Stem Cell Exosomes Granted INCI Status, Advancing into Global Cosmetic Ingredient Market
exosome manufacturing platformFlexible Cell Culture Systems: Supports multiple cell lines including HEK293, MSC, K562, and iPSC.Scalable and Robust Processes: Scalable from 2L to 50L bioreactors, enabling seamless transition from R&D to commercial production.High
More news about: Porton Advanced
May 05, 2026, 16:15 ET Factor Bioscience to Deliver Seven Presentations at the American Society of Gene & Cell Therapy (ASGCT) 29th Annual Meeting
treating solid tumors (FACT-112), as well as recent advances in Factor's RNA-based cell reprogramming technologies-Factor to reveal two novel iPSC-derived mesenchymal stem cell (iMSC) programs: Hypoimmune iMSCs for muscular dystrophy and HTRA1-expressing iMSCs for neurodegenerative disorders
More news about: Factor Bioscience
Apr 30, 2026, 11:34 ET Colossal Biosciences Expands De-extinction Portfolio with Iconic Bluebuck
artificial gametes, supporting assisted reproduction efforts for living antelope populations that are difficult to breed through conventional means. The roan iPSC platform thus serves as both the genomic surrogate for the bluebuck de-extinction program and a durable conservation tool for bovid species more broadly."iPSCs
More news about: Colossal Biosciences Inc.
Apr 30, 2026, 08:30 ET Factor Bioscience to Showcase Engineered iMacrophages (FACT-112) Targeting Ovarian Cancer In Vivo at ISCT 2026
potential to develop FACT-112 into a safe, effective option to patients with solid tumors."Details of the oral presentation are below:"iPSC-Derived Macrophages Engineered to Express IL-12 Modulate the Tumor Microenvironment and Support T Cell Lysis of Ovarian Cancer Models" -to be presented
More news about: Factor Bioscience
Apr 28, 2026, 08:00 ET Trailhead Biosystems Expands iPSC Derived Cell Portfolio with TrailBio® Endothelial Cells
iPSC-derived endothelial cells support vascular biology, drug discovery and toxicity studiesBEACHWOOD, Ohio, April 28, 2026 /PRNewswire/ -- Trailhead Biosystems, Inc. (TrailBio.com), a biotechnology company advancing
More news about: Trailhead Biosystems Inc
Apr 21, 2026, 09:11 ET ReviR Therapeutics Receives Strategic Investment from CureCMT to Advance a First-of-its-Kind Precision Medicine Platform for CMT
An isogenic iPSC and AI-enabled disease modeling platform spanning multiple genetically defined CMT subtypes will be established to support patient stratification, accelerate RTX-117 development, and create a shared foundation for next-generation therapiesBRISBANE,
More news about: ReviR Therapeutics
Apr 14, 2026, 10:00 ET Advances in Parkinson's Disease Cell Therapy: XellSmart Launches a Multicenter Phase II Clinical Trial Following Encouraging Phase I Results
April 2026, XellSmart officially launches its multicenter Phase II registrational clinical trial of the "Clinical-Grade, Allogeneic, Off-the-Shelf, iPSC-Derived, Dopaminergic Neural Progenitor Cell Therapy (XS411) for Primary Parkinson's Disease". The trial continues to be led by Beijing Tiantan Hospital
More news about: XellSmart Biopharmaceutical (Suzhou/Shanghai) Co., Ltd.
Mar 30, 2026, 07:00 ET Matricelf Enters Strategic Collaboration with Japan's CiRA Foundation to Advance Next-Generation Regenerative Manufacturing
injury, today announced it has entered into a Collaborative Research Agreement with the CiRA Foundation, a global leader in induced pluripotent stem cell (iPSC) research and regenerative medicine. The collaboration represents a strategic step toward evaluating advanced manufacturing approaches that may
More news about: Matricelf Ltd.
Mar 23, 2026, 08:00 ET Sumitomo Pharma America Announces that its Investigational Therapy DSP-3077 Has Received FDA Orphan Drug Designation for the Treatment of Retinitis Pigmentosa
bringing a potentially innovative treatment option to people with RP."About DSP-3077DSP-3077 is an investigational allogeneic iPSC-derived 3D retinal organoid, which is processed into retinal sheets with multilayered retinal tissue structure. Retinal sheets include abundant photoreceptor
More news about: Sumitomo Pharma America
Mar 18, 2026, 09:00 ET Aspen Neuroscience Announces Positive 12‑Month Data from its ASPIRO Clinical Trial in a Late‑Breaking Oral Presentation at the AD/PD™ 2026 International Conference on Alzheimer's and Parkinson's Diseases
2026 /PRNewswire/ -- Aspen Neuroscience, a clinical-stage regenerative medicine company developing autologous induced-pluripotent stem cell (iPSC)-derived therapies to initially address neurodegenerative diseases with high unmet medical need, today announced data from its ongoing Phase 1/2a ASPIRO*
More news about: Aspen Neuroscience, Inc.
Mar 13, 2026, 08:06 ET Unixell Biotech receives IND clearance by FDA for its Allogeneic iPSC-Derived cell therapy, UX-GIP001, for focal Epilepsy
achieved a significant milestone as UX-GIP001, its iPSC-derived allogeneic cell therapy targeting focal epilepsy, secured Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA). This breakthrough marks UX-GIP001 as the first iPSC-derived allogeneic epilepsy cell therapy approved
More news about: Unixell Biotech
Mar 12, 2026, 14:42 ET Micro Electrode Array Market to Reach USD 1,991.35 Million by 2032 Amid Rising Neuroscience Research, iPSC-Based Disease Modeling, and High-Density Electrophysiology Adoption - Credence Research
laboratories increasingly depend on network-level electrophysiology readouts for disease modeling, functional phenotyping, and longitudinal monitoring of iPSC-derived neuronal systems. Over the forecast period, faster growth momentum in Asia Pacific, supported by rising research capacity and adoption of advanced
More news about: Credence Research Inc.
Mar 12, 2026, 09:00 ET Kenai Therapeutics Appoints Allen Waldrop to Board of Directors
clinical-stage biotechnology company pioneering next generation approaches to cure neurological conditions. By leveraging a proprietary, Nobel Prize-winning iPSC platform, Kenai is developing off-the-shelf, allogeneic neuron replacement and gene-modified cell therapies designed to be disease-modifying. Kenai's
More news about: Kenai Therapeutics/BIOCOM
Mar 11, 2026, 19:41 ET Locus Cell, Taiwan-Based Cell and Gene Therapy CDMO, Signs MoU with Charles River at APAC Biomanufacturing Leadership Summit
in Taiwan to support the rapidly growing CGT sector in Asia. By combining Locus Cell's advanced therapy manufacturing capabilities— including CAR-T, iPSC, and immune cell platforms — with Charles River's global expertise in biologics testing and analytical development, the Parties intend to evaluate opportunities
More news about: Locus Cell Co., Ltd.
Mar 04, 2026, 13:44 ET BrainXell Launches Human iPSC-Derived Sensory Neurons for Translational Neuroscience and Pain Biology Research
March 4, 2026 /PRNewswire/ -- BrainXell today announced the launch of its human induced pluripotent stem cell (iPSC)-derived sensory neurons, a scalable human cellular platform engineered to support reproducible functional studies in pain biology, sensory transduction,
More news about: BrainXell, Inc